Related Experiment Video
Updated: Aug 30, 2025
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
Published on: May 11, 2018
Biocompatible Porphyrin-Peptide Conjugates as Theranostic Agents Targeting the Epstein-Barr Virus
Xiong Li1, Chen Xie1, Shuai Zha1
1Department of Chemistry, Hong Kong Baptist University Kowloon, Hong Kong S.A.R., P. R. China.
Abstract:
Epstein-Barr virus (EBV) is a common human-infected virus related to many diseases and cancers. Recently, some peptides have been found to serve targeting and therapeutic roles by inhibiting EBNA1, an oncoprotein of the EBV. We herein report the conjugation of the EBNA1-targeting peptides and porphyrins which can bring synergistic effects by both introducing more specific treatments (photodynamic therapy) and improving the biocompatibility of the photosensitizer and the peptides. One of our compounds exhibited significant photo-cytotoxicity where the Lethal Concentration 50 (LC50 )=6.1 μM in EBV-positive cells. Besides, in vitro cell imaging and co-staining can also be achieved simultaneously and suggested the binding inside nucleus.
Insights
Researchers conjugated EBNA1-targeting peptides with porphyrins for synergistic cancer therapy. This novel approach shows potent phototoxicity against Epstein-Barr virus-infected cells, suggesting potential for targeted cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Photomedicine
Background:
- Epstein-Barr virus (EBV) is linked to various cancers and diseases.
- EBV's oncoprotein, EBNA1, is a target for therapeutic peptides.
- Porphyrins are photosensitizers used in photodynamic therapy.
Purpose of the Study:
- To conjugate EBNA1-targeting peptides with porphyrins.
- To evaluate the synergistic effects of the conjugated compounds.
- To assess their potential in targeted cancer therapy and imaging.
Main Methods:
- Synthesis and conjugation of EBNA1-targeting peptides with porphyrins.
- In vitro assessment of photocytotoxicity in EBV-positive cells.
- In vitro cell imaging and co-staining studies.
Main Results:
- One conjugated compound demonstrated significant photocytotoxicity with an LC50 of 6.1 μM in EBV-positive cells.
- The compound facilitated simultaneous in vitro cell imaging and co-staining.
- Evidence suggests the compound binds within the cell nucleus.
Conclusions:
- Conjugating EBNA1-targeting peptides with porphyrins offers a synergistic approach for cancer therapy.
- The novel compounds exhibit potent photo-cytotoxic effects and nuclear targeting.
- This strategy holds promise for enhanced photodynamic therapy against EBV-associated cancers.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019